These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33472023)

  • 41. A Novel and Selective p38 Mitogen-Activated Protein Kinase Inhibitor Attenuates LPS-Induced Neuroinflammation in BV2 Microglia and a Mouse Model.
    Gee MS; Kim SW; Kim N; Lee SJ; Oh MS; Jin HK; Bae JS; Inn KS; Kim NJ; Lee JK
    Neurochem Res; 2018 Dec; 43(12):2362-2371. PubMed ID: 30327995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding of [3H]bryostatin 4 to protein kinase C.
    Lewin NE; Dell'Aquila ML; Pettit GR; Blumberg PM; Warren BS
    Biochem Pharmacol; 1992 May; 43(9):2007-14. PubMed ID: 1596288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.
    Ryckbosch SM; Wender PA; Pande VS
    Nat Commun; 2017 Feb; 8(1):6. PubMed ID: 28232750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delta-protein kinase C phosphorylation parallels inhibition of nerve growth factor-induced differentiation independent of changes in Trk A and MAP kinase signalling in PC12 cells.
    Wooten MW; Seibenhener ML; Heikkila JE; Mischak H
    Cell Signal; 1998 Apr; 10(4):265-76. PubMed ID: 9617484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of the Role and Active Sites of PKC-Delta-Like from Lamprey in Innate Immunity.
    Xu Y; Zhao H; Tian Y; Ren K; Zheng N; Li Q
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31323909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
    Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
    Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting microglia attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations.
    Groh J; Klein D; Berve K; West BL; Martini R
    Glia; 2019 Feb; 67(2):277-290. PubMed ID: 30565754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
    Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
    Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
    Bear HD; McFadden AW; Kostuchenko PJ; Lipshy KA; Hamad GG; Turner AJ; Roberts JD; Carr M; Carr S; Grant S
    Anticancer Drugs; 1996 May; 7(3):299-306. PubMed ID: 8792004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
    Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
    Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model.
    Schrott L; Yi P; Jackson K; Jackson GS; Webb C; Minagar A; Yun JW; Purdum G; Rios DJ; Tyler TA; Vizcanio MI; Castor JL; Castor T; Alexander JS
    Curr Alzheimer Res; 2020; 17(14):1302-1310. PubMed ID: 33602091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification.
    Wender PA; Baryza JL
    Org Lett; 2005 Mar; 7(6):1177-80. PubMed ID: 15760168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism.
    Díaz L; Martínez-Bonet M; Sánchez J; Fernández-Pineda A; Jiménez JL; Muñoz E; Moreno S; Álvarez S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Jul; 5():12442. PubMed ID: 26199173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships.
    Kedei N; Kraft MB; Keck GE; Herald CL; Melody N; Pettit GR; Blumberg PM
    J Nat Prod; 2015 Apr; 78(4):896-900. PubMed ID: 25808573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
    Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
    Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.
    Keck GE; Li W; Kraft MB; Kedei N; Lewin NE; Blumberg PM
    Org Lett; 2009 Jun; 11(11):2277-80. PubMed ID: 19419164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs.
    Wender PA; Horan JC; Verma VA
    Org Lett; 2006 Nov; 8(23):5299-302. PubMed ID: 17078702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs.
    Wender PA; Clarke MO; Horan JC
    Org Lett; 2005 May; 7(10):1995-8. PubMed ID: 15876038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
    Wender PA; Hinkle KW; Koehler MF; Lippa B
    Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.